Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Drug Safety Oversight Board Adds Staff To Manage Operations

Executive Summary

FDA is adding three new staffers dedicated to working full time on the operations and communications of the Drug Safety Oversight Board

You may also be interested in...



DSOB adds staffer

Mary Mease joins FDA's Drug Safety Oversight Board as a science policy analyst, the agency announced Nov. 4. Mease previously worked in the Center for Drug Evaluation & Research's Division of Scientific Investigators; she has also worked as a safety evaluator in the Office of Drug Safety's Division of Drug Risk Evaluation. Mease's appointment is expected to complete the board's staff (1"The Pink Sheet" Oct. 24, 2005, p. 5)...

DSOB adds staffer

Mary Mease joins FDA's Drug Safety Oversight Board as a science policy analyst, the agency announced Nov. 4. Mease previously worked in the Center for Drug Evaluation & Research's Division of Scientific Investigators; she has also worked as a safety evaluator in the Office of Drug Safety's Division of Drug Risk Evaluation. Mease's appointment is expected to complete the board's staff (1"The Pink Sheet" Oct. 24, 2005, p. 5)...

FDA Public Meeting On Rx Risk, Benefit Communication Slated For December

FDA will hold a public hearing on ways to better communicate information about drug risks and benefits, FDA Drug Safety Oversight Board Executive Director Susan Cummins said at the PDA/FDA Joint Regulatory Conference in Washington, D.C. on Sept. 13

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS046468

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel